B-intervention	0	4	Oral
I-intervention	5	13	curcumin
O	14	17	for
B-condition	18	27	radiation
I-condition	28	38	dermatitis
O	38	39	:
O	40	41	a
O	42	46	URCC
O	47	52	NCORP
O	53	58	study
O	59	61	of
B-total-participants	62	65	686
B-eligibility	66	72	breast
I-eligibility	73	79	cancer
I-eligibility	80	88	patients
O	88	89	.

O	90	97	Despite
O	98	106	advances
O	107	109	in
O	110	117	medical
O	118	128	technology
O	128	129	,
O	130	139	radiation
O	140	150	dermatitis
O	151	157	occurs
O	158	160	in
O	161	163	95
O	163	164	%
O	165	167	of
O	168	176	patients
O	177	186	receiving
O	187	196	radiation
O	197	204	therapy
O	205	206	(
O	206	208	RT
O	208	209	)
O	210	213	for
O	214	220	cancer
O	220	221	.

O	222	231	Currently
O	231	232	,
O	233	238	there
O	239	241	is
O	242	244	no
O	245	253	standard
O	254	257	and
O	258	267	effective
O	268	277	treatment
O	278	281	for
O	282	285	the
O	286	296	prevention
O	297	299	or
O	300	307	control
O	308	310	of
O	311	320	radiation
O	321	331	dermatitis
O	331	332	.

O	333	336	The
O	337	341	goal
O	342	344	of
O	345	348	the
O	349	354	study
O	355	358	was
O	359	361	to
O	362	371	determine
O	372	375	the
O	376	384	efficacy
O	385	387	of
O	388	392	oral
O	393	401	curcumin
O	401	402	,
O	403	406	one
O	407	409	of
O	410	413	the
O	414	426	biologically
O	427	433	active
O	434	444	components
O	445	447	in
O	448	456	turmeric
O	456	457	,
O	458	460	at
O	461	469	reducing
O	470	479	radiation
O	480	490	dermatitis
O	491	499	severity
O	500	501	(
O	501	504	RDS
O	504	505	)
O	506	508	at
O	509	512	the
O	513	516	end
O	517	519	of
O	520	522	RT
O	522	523	,
O	524	529	using
O	530	533	the
O	534	537	RDS
O	538	543	scale
O	543	544	,
O	545	553	compared
O	554	556	to
B-control	557	564	placebo
O	564	565	.

O	566	570	This
O	571	574	was
O	575	576	a
O	577	586	multisite
O	586	587	,
O	588	598	randomized
O	598	599	,
O	600	606	double
O	606	607	-
O	607	614	blinded
O	614	615	,
O	616	623	placebo
O	623	624	-
O	624	634	controlled
O	635	640	trial
O	641	643	of
B-total-participants	644	647	686
O	648	654	breast
O	655	661	cancer
O	662	670	patients
O	670	671	.

O	672	680	Patients
O	681	685	took
O	686	690	four
O	691	694	500
O	694	695	-
O	695	697	mg
O	698	706	capsules
O	707	709	of
O	710	717	placebo
O	718	720	or
O	721	729	curcumin
O	730	735	three
O	736	741	times
O	742	747	daily
O	748	758	throughout
O	759	764	their
O	765	775	prescribed
O	776	782	course
O	783	785	of
O	786	788	RT
O	789	794	until
O	795	796	1
O	797	801	week
O	802	806	post
O	806	807	-
O	807	809	RT
O	809	810	.

O	811	812	A
O	813	818	total
O	819	821	of
B-total-participants	822	825	686
O	826	834	patients
O	835	839	were
O	840	848	included
O	849	851	in
O	852	855	the
O	856	861	final
O	862	870	analyses
O	871	872	(
O	872	874	87
O	874	875	.
O	875	876	5
O	876	877	%
B-ethinicity	878	883	white
O	884	891	females
O	891	892	,
O	893	897	mean
O	898	901	age
O	902	903	=
B-age	904	906	58
O	906	907	)
O	907	908	.

O	909	915	Linear
O	916	921	mixed
O	921	922	-
O	922	927	model
O	928	936	analyses
O	937	949	demonstrated
O	950	954	that
O	955	963	curcumin
O	964	967	did
O	968	971	not
O	972	978	reduce
B-outcome	979	988	radiation
I-outcome	989	999	dermatitis
I-outcome	1000	1008	severity
O	1009	1011	at
O	1012	1015	the
O	1016	1019	end
O	1020	1022	of
O	1023	1025	RT
O	1026	1034	compared
O	1035	1037	to
O	1038	1045	placebo
O	1046	1047	(
O	1047	1048	B
O	1049	1050	(
O	1050	1052	95
O	1052	1053	%
O	1054	1056	CI
O	1056	1057	)
O	1058	1059	=
O	1060	1061	0
O	1061	1062	.
O	1062	1065	044
O	1066	1067	(
O	1067	1068	-
O	1069	1070	0
O	1070	1071	.
O	1071	1074	101
O	1074	1075	,
O	1076	1077	0
O	1077	1078	.
O	1078	1081	188
O	1081	1082	)
O	1082	1083	,
O	1084	1085	p
O	1086	1087	=
O	1088	1089	0
O	1089	1090	.
O	1090	1093	552
O	1093	1094	)
O	1094	1095	.

O	1096	1101	Fewer
O	1102	1110	curcumin
O	1111	1119	patients
O	1120	1124	with
O	1125	1128	RDS
O	1129	1130	>
O	1131	1132	3
O	1132	1133	.
O	1133	1134	0
O	1135	1144	suggested
O	1145	1146	a
B-outcome	1147	1152	trend
I-outcome	1153	1159	toward
I-outcome	1160	1167	reduced
I-outcome	1168	1176	severity
O	1177	1178	(
B-iv-bin-percent	1178	1179	7
I-iv-bin-percent	1179	1180	.
I-iv-bin-percent	1180	1181	4
O	1182	1184	vs
O	1184	1185	.
B-cv-bin-percent	1186	1188	12
I-cv-bin-percent	1188	1189	.
I-cv-bin-percent	1189	1190	9
I-cv-bin-percent	1190	1191	%
O	1191	1192	,
O	1193	1194	p
O	1195	1196	=
O	1197	1198	0
O	1198	1199	.
O	1199	1202	082
O	1202	1203	)
O	1203	1204	.

O	1205	1212	Patient
O	1212	1213	-
O	1213	1221	reported
O	1222	1229	changes
O	1230	1232	in
B-outcome	1233	1237	pain
O	1237	1238	,
B-outcome	1239	1247	symptoms
O	1247	1248	,
O	1249	1252	and
B-outcome	1253	1260	quality
I-outcome	1261	1263	of
I-outcome	1264	1268	life
O	1269	1273	were
O	1274	1277	not
O	1278	1291	statistically
O	1292	1303	significant
O	1304	1311	between
O	1312	1316	arms
O	1316	1317	.

O	1318	1322	Oral
O	1323	1331	curcumin
O	1332	1335	did
O	1336	1339	not
O	1340	1353	significantly
O	1354	1360	reduce
B-outcome	1361	1370	radiation
I-outcome	1371	1381	dermatitis
I-outcome	1382	1390	severity
O	1391	1399	compared
O	1400	1402	to
O	1403	1410	placebo
O	1410	1411	.

O	1412	1415	The
O	1416	1420	skin
O	1421	1427	rating
O	1428	1437	variation
O	1438	1441	and
O	1442	1447	broad
O	1448	1459	eligibility
O	1460	1468	criteria
O	1469	1474	could
O	1475	1478	not
O	1479	1486	account
O	1487	1490	for
O	1491	1494	the
O	1495	1507	undetectable
O	1508	1519	therapeutic
O	1520	1526	effect
O	1526	1527	.

O	1528	1530	An
O	1531	1540	objective
O	1541	1548	measure
O	1549	1552	for
O	1553	1562	radiation
O	1563	1573	dermatitis
O	1574	1582	severity
O	1583	1586	and
O	1587	1594	further
O	1595	1606	exploration
O	1607	1610	for
O	1611	1613	an
O	1614	1623	effective
O	1624	1633	treatment
O	1634	1637	for
O	1638	1647	radiation
O	1648	1658	dermatitis
O	1659	1661	is
O	1662	1671	warranted
O	1671	1672	.
